- Home
- Publications
- Publication Search
- Publication Details
Title
MET targeting: time for a rematch
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-02-08
DOI
10.1038/s41388-020-1193-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CAR T-cell Therapy: A New Era in Cancer Immunotherapy
- (2018) Miliotou N. Androulla et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- C-MET inhibitors for advanced non-small cell lung cancer
- (2018) Giulia Pasquini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer
- (2018) Ning Li et al. Translational Oncology
- Phase 1 Study of AMG 337, a Highly Selective Small-Molecule MET Inhibitor, in Patients With Advanced Solid Tumors
- (2018) David S. Hong et al. CLINICAL CANCER RESEARCH
- Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
- (2017) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping
- (2017) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
- (2017) Conor A. Bradley et al. Nature Reviews Clinical Oncology
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer
- (2017) Samer Al-Saad et al. PLoS One
- Concurrent administration of anti-HER2 therapy and radiotherapy: Systematic review
- (2017) Fabien Mignot et al. RADIOTHERAPY AND ONCOLOGY
- Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
- (2017) Julia Tchou et al. Cancer Immunology Research
- MET Amplification and Response to MET Inhibitors in Stage IV Lung Adenocarcinoma
- (2017) Moushumi Suryavanshi et al. Oncology Research and Treatment
- CAR T-cell immunotherapy of MET-expressing malignant mesothelioma
- (2017) Thivyan Thayaparan et al. OncoImmunology
- Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
- (2017) Manish A. Shah et al. JAMA Oncology
- Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001
- (2016) A. Shaw et al. ANNALS OF ONCOLOGY
- Regulation of theMEToncogene: molecular mechanisms
- (2016) Jack Zhang et al. CARCINOGENESIS
- ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET –Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence
- (2016) Jieyi Wang et al. CLINICAL CANCER RESEARCH
- MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
- (2016) J. H. Tong et al. CLINICAL CANCER RESEARCH
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
- (2016) Mark M. Awad et al. JOURNAL OF CLINICAL ONCOLOGY
- Unbiased identification of substrates of protein tyrosine phosphatase ptp-3 in C. elegans
- (2016) Christopher J. Mitchell et al. Molecular Oncology
- Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
- (2016) Kaichao Feng et al. Science China-Life Sciences
- Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
- (2016) M. Bahcall et al. Cancer Discovery
- Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?
- (2016) Witthawat Ariyawutyakorn et al. Journal of Cancer
- Efficacy of crizotinib in ALK fusion variants
- (2016) Tetsu Kobayashi et al. Journal of Thoracic Disease
- A systematic review of geographical variation in access to chemotherapy
- (2015) Charlotte Chamberlain et al. BMC CANCER
- Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites
- (2015) Wafik S. El-Deiry et al. CANCER BIOLOGY & THERAPY
- Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
- (2015) I. Watermann et al. Diagnostic Pathology
- Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
- (2015) R. Pagliarini et al. EMBO REPORTS
- 2353 Data from a phase Ib/II trial of the oral c-Met inhibitor tepotinib (MSC2156119J) as first-line therapy in Asian patients with advanced hepatocellular carcinoma
- (2015) S. Qin et al. EUROPEAN JOURNAL OF CANCER
- Essential roles of Gab1 tyrosine phosphorylation in growth factor-mediated signaling and angiogenesis
- (2015) Weiye Wang et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial.
- (2015) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- A mutation ofMET, encoding hepatocyte growth factor receptor, is associated with humanDFNB97hearing loss
- (2015) Ghulam Mujtaba et al. JOURNAL OF MEDICAL GENETICS
- NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era:
- (2015) Caroline McNeil JNCI-Journal of the National Cancer Institute
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic value of c-Met in colorectal cancer: A meta-analysis
- (2015) Yan Liu WORLD JOURNAL OF GASTROENTEROLOGY
- Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
- (2015) P. K. Paik et al. Cancer Discovery
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer
- (2015) E. L. Kwak et al. Cancer Discovery
- NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era:
- (2015) Caroline McNeil JNCI-Journal of the National Cancer Institute
- Discovery of Fully Human Anti-MET Monoclonal Antibodies with Antitumor Activity against Colon Cancer Tumor Models In Vivo
- (2015) Edward Htun van der Horst et al. NEOPLASIA
- Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer
- (2014) Adrian G. Sacher et al. CANCER
- Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
- (2014) H. Koeppen et al. CLINICAL CANCER RESEARCH
- LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
- (2014) L. Liu et al. CLINICAL CANCER RESEARCH
- Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+T Cells
- (2014) Keisuke Watanabe et al. JOURNAL OF IMMUNOLOGY
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- MET inhibitors start on road to recovery
- (2014) Ken Garber NATURE REVIEWS DRUG DISCOVERY
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the oncogenic Met receptor by antibodies and gene therapy
- (2014) E Vigna et al. ONCOGENE
- EGF Receptor Activates MET through MAPK to Enhance Non-Small Cell Lung Carcinoma Invasion and Brain Metastasis
- (2013) J. L. Breindel et al. CANCER RESEARCH
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
- (2013) C. Basilico et al. CLINICAL CANCER RESEARCH
- Expression of HGF and Met in Human Tissues of Colorectal Cancers: Biological and Clinical Implications for Synchronous Liver Metastasis
- (2013) Yan-lai Sun et al. International Journal of Medical Sciences
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor
- (2013) Elisa Vigna et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Developing biomarkers to predict benefit from HGF/MET pathway inhibitors
- (2013) Hartmut Koeppen et al. JOURNAL OF PATHOLOGY
- AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival
- (2013) Smita Salian-Mehta et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants
- (2013) Michaela Medová et al. MOLECULAR CANCER THERAPEUTICS
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2013) Alberto Bardelli et al. Cancer Discovery
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- MET and Phosphorylated MET as Potential Biomarkers in Lung Cancer
- (2012) Maria Tretiakova et al. JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy
- (2012) M. J. W. D. Vosjan et al. MOLECULAR CANCER THERAPEUTICS
- Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody
- (2012) J M Lee et al. ONCOGENE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer
- (2011) Yuji Toiyama et al. INTERNATIONAL JOURNAL OF CANCER
- Receptor-type Protein Tyrosine Phosphatase β (RPTP-β) Directly Dephosphorylates and Regulates Hepatocyte Growth Factor Receptor (HGFR/Met) Function
- (2011) Yiru Xu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer
- (2011) Francesca De Bacco et al. JNCI-Journal of the National Cancer Institute
- Anti-MET Targeted Therapy Has Come of Age: The First Durable Complete Response with MetMAb in Metastatic Gastric Cancer
- (2011) Y. Feng et al. Cancer Discovery
- Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence
- (2011) D. V. T. Catenacci et al. Cancer Discovery
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors
- (2010) P. J. Rosen et al. CLINICAL CANCER RESEARCH
- Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody
- (2010) Giovanni Pacchiana et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A Disintegrin and Metalloproteinase-10 (ADAM-10) Mediates DN30 Antibody-induced Shedding of the Met Surface Receptor
- (2010) Florian Schelter et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Biochemical Characterization of AMG 102: A Neutralizing, Fully Human Monoclonal Antibody to Human and Nonhuman Primate Hepatocyte Growth Factor
- (2010) T. L. Burgess et al. MOLECULAR CANCER THERAPEUTICS
- TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non-Small Cell Lung Cancer with an EGFR Mutation
- (2010) W. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- MET signalling: principles and functions in development, organ regeneration and cancer
- (2010) Livio Trusolino et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Src and FAK mediate cell-matrix adhesion-dependent activation of met during transformation of breast epithelial cells
- (2009) Angela Y. Hui et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Down-Regulation of the Met Receptor Tyrosine Kinase by Presenilin-dependent Regulated Intramembrane Proteolysis
- (2009) Bénédicte Foveau et al. MOLECULAR BIOLOGY OF THE CELL
- Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression
- (2009) Nabil Ahmed et al. MOLECULAR THERAPY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma
- (2008) Erina Nakamura et al. CANCER SCIENCE
- Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer
- (2008) Yoshihiko Kitajima et al. CANCER SCIENCE
- Regulation of the Met Receptor-tyrosine Kinase by the Protein-tyrosine Phosphatase 1B and T-cell Phosphatase
- (2008) Veena Sangwan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met
- (2008) Cristina Basilico et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started